
IRTC — iRhythm Technologies Inc
NASDAQ · Healthcare · Medical Devices
$122.35
+$3.41 (+2.87%)
iRhythm Technologies Inc (IRTC) is a medical devices company listed on NASDAQ. It is led by Quentin S. Blackford, based in 699 8th Street, San Francisco, CA, United States, 94103, with about 2,000 employees. iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. The company offers Zio ambulatory cardiac monitoring services, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. It also provides Zio Monitor System, a prescription-only remote electrocardiogram (ECG) monitoring system consisting a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days; Zio XT System, a prescription-only remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and Zio ECG Utilization Software System, which supports the capture and analysis of ECG data. In addition, the company offers Zio AT System, a prescription-only remote ECG monitoring system, which consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days, as well as incorporates the Zio AT wireless gateway to provide connectivity between the patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. iRhythm Technologies, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Latest reported IRTC revenue for 2025-09-30 was $192.9M. Net income was -$50.1M. Revenue was up 3.3% from 2025-06-30 to 2025-09-30. IRTC currently screens at market cap $4.55B.
Use this IRTC page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the IRTC quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the IRTC SEC filings page. Lician reads the product cache first so this HTML stays unique to iRhythm Technologies Inc even when a live quote feed is slow.
About iRhythm Technologies Inc
iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. The company offers Zio ambulatory cardiac monitoring services, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. It also provides Zio Monitor System, a prescription-only remote electrocardiogram (ECG) monitoring system consisting a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days; Zio XT System, a prescription-only remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and Zio ECG Utilization Software System, which supports the capture and analysis of ECG data. In addition, the company offers Zio AT System, a prescription-only remote ECG monitoring system, which consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days, as well as incorporates the Zio AT wireless gateway to provide connectivity between the patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. iRhythm Technologies, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
IRTC Key Statistics
Market Cap
$4.55B
Volume
171,844
Previous Close
$125.25
Day Range
$123.37 – $125.62
EPS
-$3.63
Revenue
$591.84M
Net Income
-$113.29M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+20.1%
Profit Margin
-19.1%
Employees
2,000
IRTC Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $591.84M | $492.68M | $410.92M | $322.82M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$113.29M | -$123.41M | -$116.16M | -$101.36M |
| EPS (Diluted) | -$3.63 | -$4.04 | -$3.88 | -$3.46 |
Total Assets
$931.45M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$419.60M
Operating Cash Flow
$3.39M
Free Cash Flow
$0.00
iRhythm Technologies Inc Company Information
- President, CEO & Director
- Quentin S. Blackford
- Headquarters
- 699 8th Street, San Francisco, CA, United States, 94103
- Website
- www.irhythmtech.com
- Phone
- 415 632 5700
- IPO / Founded
- 2016-10-20
- Sector
- Healthcare
- Industry
- Medical Devices